Company Profile: Agile Sciences

CED Life Science Conference 2018 - Innovation Room                                                  
Sub-sector: Biotech and Pharmaceutical                                                                
Year Founded: 2007

Agile Sciences is developing a more effective therapeutic strategy for treating multidrug resistant (MDR) bacterial infections. The company’s core technology consists of a new class of 2-aminoimidazole (2-AI) small molecules that inhibit bacterial defense mechanisms through a novel mode of action resulting in enhanced antibiotic activity by inhibiting and dispersing bacterial communities, known as biofilms, and restoring antibiotic susceptibility in drug resistant infections. Agile Sciences is targeting three therapeutic areas: 1) treatment of MDR bacterial infections; 2) treatment of lung infections in cystic fibrosis (CF) patients; and 3) treatment of chronic wound infections.

John Cavanagh (Co-Founder)
Christian Melander (Co-Founder)
Malcolm Thomas (CEO)


  • Agile Sciences has completed initial pharmacological assessments for its lead compounds in all three of its drug development programs (Cystic Fibrosis, chronic wound, and hospital acquired multidrug resistant Gram-negative infections). The Company is executing a milestone-based approach to achieve submission of an IND in 2019 in each of the three targeted therapeutic areas.
  • Accolades: Agile Sciences has successfully obtained over $13M in NIH funding including 13 Small Business grants and $4M contract to advance development of its pipeline. It has also received grants from the Cystic Fibrosis Foundation and the Bay Area Lyme Foundation.
  • Funding: $15 Million

CED; NC State Office of Technology Transfer (OTT), One NC Small Business Program

Malcolm Thomas
Raleigh, NC

Past CED Life Science Conference selection: 2017 - Lightning Round & Innovation Room

Learn more about the CED Life Science Conference.